Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 617, Issue 1-3, Pages 23-27Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2009.07.003
Keywords
Endostatin; Angiogenesis; Chemotherapy; Synergistic interaction
Categories
Funding
- State Ministry of Science and Technology of China [2006AA02Z19E]
- 98511 Project from Nanjing University [BK2008150]
- Natural Science Foundation of Jiangsu Province [30670671]
- National Natural Science Foundation of China [BK2006713]
- Natural Science Foundation of Jiangsu Province, China
- State Educational Ministry of China [20050284025]
Ask authors/readers for more resources
Endostatin is an endogenous inhibitor of angiogenesis and has been shown to exhibit potent inhibitory activity in certain mice tumor models. In this study, a treatment strategy of combining recombinant human endostatin (rhEndostatin) and chemotherapeutics was implemented to evaluate the therapeutic efficacy of rhEndostatin against solid tumors. The antitumor effect of rhEndostatin in combination with several chemotherapeutic drugs, e.g., 5-fluorouracil, cyclophosphamide, methotrexate, and mitomycin C, on human QGY liver tumor and mice H22 liver tumor was compared with that of rhEndostatin treatment alone. The results showed that the combination of rhEndostatin and chemotherapeutic drugs resulted in a more potent inhibition of tumor growth. The potential advantages of rhEndostatin plus tumor chemotherapy provide a basis for further clinical trials of rhEndostatin. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available